Patient demographics
| . | Blinatumomab . | Tisagenlecleucel infused . | Tisagenlecleucel enrolled . |
|---|---|---|---|
| . | N = 70 . | N = 79 . | N = 97 . |
| Age (years), median (range) | 8.0 (<1-17.0) | 11.0 (3.0-24.0) | 11.0 (3-27) |
| Male, n (%)* | 47 (67.1) | 45 (57.0) | 54 (55.7) |
| Geographic region, n (%)* | |||
| United States/Canada | 22 (31.4) | 44 (55.7) | 56 (57.7) |
| European Union | 48 (68.6) | 28 (35.4) | 32 (33.0) |
| Other | 0 (0.0) | 7 (8.9) | 9 (9.3) |
| Karnofsky/Lansky performance status ≥50%, n (%)* | 70 (100.0) | 79 (100.0) | 79 (81.4) |
| Previous alloSCT, n (%) | 40 (57.1) | 48 (60.8) | 58 (59.7) |
| Previous relapses, n (%) | |||
| 0 | 2 (2.9) | 6 (7.6) | 8 (8.3) |
| 1 | 31 (44.3) | 21 (26.6) | 29 (29.9) |
| 2 | 29 (41.4) | 17 (21.5) | 18 (18.6) |
| ≥3 | 8 (11.4) | 35 (44.3) | 42 (43.3) |
| Months since last relapse, median (range)* | 2.9 (0.4-49.8) | 3.5 (1.5-13.8) | NA |
| Bone marrow blast count ≥50%, n (%)* | 52 (74.3) | 54 (68.4) | 70 (72.2) |
| Refractory to last treatment, n (%) | 39 (56) | 77 (53.8) | 94 (55) |
| . | Blinatumomab . | Tisagenlecleucel infused . | Tisagenlecleucel enrolled . |
|---|---|---|---|
| . | N = 70 . | N = 79 . | N = 97 . |
| Age (years), median (range) | 8.0 (<1-17.0) | 11.0 (3.0-24.0) | 11.0 (3-27) |
| Male, n (%)* | 47 (67.1) | 45 (57.0) | 54 (55.7) |
| Geographic region, n (%)* | |||
| United States/Canada | 22 (31.4) | 44 (55.7) | 56 (57.7) |
| European Union | 48 (68.6) | 28 (35.4) | 32 (33.0) |
| Other | 0 (0.0) | 7 (8.9) | 9 (9.3) |
| Karnofsky/Lansky performance status ≥50%, n (%)* | 70 (100.0) | 79 (100.0) | 79 (81.4) |
| Previous alloSCT, n (%) | 40 (57.1) | 48 (60.8) | 58 (59.7) |
| Previous relapses, n (%) | |||
| 0 | 2 (2.9) | 6 (7.6) | 8 (8.3) |
| 1 | 31 (44.3) | 21 (26.6) | 29 (29.9) |
| 2 | 29 (41.4) | 17 (21.5) | 18 (18.6) |
| ≥3 | 8 (11.4) | 35 (44.3) | 42 (43.3) |
| Months since last relapse, median (range)* | 2.9 (0.4-49.8) | 3.5 (1.5-13.8) | NA |
| Bone marrow blast count ≥50%, n (%)* | 52 (74.3) | 54 (68.4) | 70 (72.2) |
| Refractory to last treatment, n (%) | 39 (56) | 77 (53.8) | 94 (55) |
Variables describe patients at baseline of their respective trials.
At enrollment, blinatumomab patients had >25% bone marrow blasts; tisagenlecleucel patients had ≥5% lymphoblasts in bone marrow.
Not considered in adjustment because of unavailability of patient-level data within the blinatumomab dataset published in Gore et al.20